Manel Cascallo

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications

Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy.

Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 12, 2026

Toxicity and Biodistribution of the Oncolytic Virus VCN-01 Following Intracranial Injection in Syrian Hamsters.

Toxicity and Biodistribution of the Oncolytic Virus VCN-01 Following Intracranial Injection in Syrian Hamsters.

Journal: Human gene therapy
Published: August 29, 2025

Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors.

Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors.

Journal: Journal for immunotherapy of cancer
Published: March 01, 2022

VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects.

VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects.

Journal: Journal for immunotherapy of cancer
Published: September 11, 2021

Oncolytic adenovirus with hyaluronidase activity that evades neutralizing antibodies: VCN-11.

Oncolytic adenovirus with hyaluronidase activity that evades neutralizing antibodies: VCN-11.

Journal: Journal of controlled release : official journal of the Controlled Release Society
Published: November 30, 2020

The oncolytic adenovirus VCN-01 promotes anti-tumor effect in primitive neuroectodermal tumor models.

The oncolytic adenovirus VCN-01 promotes anti-tumor effect in primitive neuroectodermal tumor models.

Journal: Scientific reports
Published: June 04, 2019

A Phase 1 Trial of Oncolytic Adenovirus ICOVIR-5 Administered Intravenously to Cutaneous and Uveal Melanoma Patients.

A Phase 1 Trial of Oncolytic Adenovirus ICOVIR-5 Administered Intravenously to Cutaneous and Uveal Melanoma Patients.

Journal: Human gene therapy
Published: September 21, 2018

Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01.

Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01.

Journal: Science translational medicine
Published: June 13, 2018

Correction: Characterization of the Antiglioma Effect of the Oncolytic Adenovirus VCN-01.

Correction: Characterization of the Antiglioma Effect of the Oncolytic Adenovirus VCN-01.

Journal: PloS one
Published: June 10, 2016

Characterization of the Antiglioma Effect of the Oncolytic Adenovirus VCN-01.

Characterization of the Antiglioma Effect of the Oncolytic Adenovirus VCN-01.

Journal: PloS one
Published: September 14, 2015

The Oncolytic Adenovirus VCN-01 as Therapeutic Approach Against Pediatric Osteosarcoma.

The Oncolytic Adenovirus VCN-01 as Therapeutic Approach Against Pediatric Osteosarcoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 07, 2015

Safety and efficacy of VCN-01, an oncolytic adenovirus combining fiber HSG-binding domain replacement with RGD and hyaluronidase expression.

Safety and efficacy of VCN-01, an oncolytic adenovirus combining fiber HSG-binding domain replacement with RGD and hyaluronidase expression.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 14, 2014
Showing 1-12 of 17

Last Updated: 09/26/2026